文献速递骨软组织肉瘤与黑色素瘤

加尼妥单抗联合间期压缩化疗治疗新诊断转移性尤文肉瘤的随机III期试验:儿童肿瘤协作组报告

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
PubMed 文献 · J Clin Oncol · 2023-01-20

儿童肿瘤协作组AEWS1221试验将298例新诊断转移性尤文肉瘤患者1:1随机分配至标准间期压缩VDC/IE方案组或联合加尼妥单抗组。实验组3年无事件生存率为39.1%(95%CI 31.3-46.7),标准组为37.4%(95%CI 29.3-45.5),分层EFS事件风险比1.00(95%CI 0.76-1.33,单侧P=0.50)。加尼妥单抗未显著降低EFS事件风险,且可能与毒性增加相关。

要点

  • 加尼妥单抗联合间期压缩化疗未显著改善新诊断转移性尤文肉瘤患者的EFS。
  • 实验组3年EFS为39.1%,标准组为37.4%,分层EFS事件HR为1.00(95%CI 0.76-1.33,单侧P=0.50)。
  • 实验组报告更多胸部放疗后肺炎,发热性中性粒细胞减少和ALT升高发生率名义上更高。

核心结论

  • 加尼妥单抗加入间期压缩化疗未显著降低新诊断转移性尤文肉瘤患者的EFS事件风险,结局与既往未使用IGF-1R抑制或间期压缩的试验相似。
  • 加尼妥单抗的加入可能与毒性增加相关。

研究设计与样本

  • 儿童肿瘤协作组AEWS1221随机III期试验,入组患者1:1随机分配至标准组或实验组。
  • 标准组方案为间期压缩长春新碱/多柔比星/环磷酰胺与异环磷酰胺/依托泊苷每2周交替(VDC/IE)。
  • 实验组方案为VDC/IE联合加尼妥单抗于周期开始时给药,并在常规治疗后作为单药每3周一次持续6个月。
  • 计划样本量300例,预计提供81%把握度检测实验组相比标准组EFS风险比≤0.67,单侧α=0.025。
  • 共298例合格患者入组(标准组148例;实验组150例)。

主要发现

  • 3年EFS估计值:标准组37.4%(95%CI 29.3-45.5),实验组39.1%(95%CI 31.3-46.7)。
  • 分层EFS事件风险比:实验组相比标准组为1.00(95%CI 0.76-1.33;单侧P=0.50)。
  • 3年总生存估计值:标准组59.5%(95%CI 50.8-67.3),实验组56.7%(95%CI 48.3-64.2)。
  • 实验组报告更多胸部放疗后肺炎,以及发热性中性粒细胞减少和ALT升高发生率名义上更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addition of the IGF-1R monoclonal antibody ganitumab to interval-compressed chemotherapy improves event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma. METHODS: Patients were randomly assigned 1:1 at enrollment to standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE) or to experimental arm (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy). A planned sample size of 300 patients was projected to provide 81% power to detect an EFS hazard ratio of 0.67 or smaller for the experimental arm compared with the standard arm with a one-sided α of .025. RESULTS: Two hundred ninety-eight eligible patients enrolled (148 in standard arm; 150 in experimental arm). The 3-year EFS estimates were 37.4% (95% CI, 29.3 to 45.5) for the standard arm and 39.1% (95% CI, 31.3 to 46.7) for the experimental arm (stratified EFS-event hazard ratio for experimental arm 1.00; 95% CI, 0.76 to 1.33; 1-sided, P = .50). The 3-year overall survival estimates were 59.5% (95% CI, 50.8 to 67.3) for the standard arm and 56.7% (95% CI, 48.3 to 64.2) for the experimental arm. More cases of pneumonitis after radiation involving thoracic fields and nominally higher rates of febrile neutropenia and ALT elevation were reported on the experimental arm. CONCLUSION: Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. DuBois SG, Krailo MD, Glade-Bender J, et al. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023. PMID: 36669140. doi:10.1200/JCO.22.01815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。